Evidence map›Paper›PMID 37454672›Full record

ArticleThe Lancet. Infectious diseases2023

Mortality associated with third-generation cephalosporin resistance in Enterobacterales bloodstream infections at eight sub-Saharan African hospitals (MBIRA): a prospective cohort study.

Alexander M Aiken, Andrea M Rehman, Marlieke E A de Kraker, Lola Madrid, Meron Kebede, Appiah-Korang Labi, Noah Obeng-Nkrumah, Brian Nyamwaya, Eunice Kagucia, Derek Cocker and 13 more

Open access · hybridAbstract read
In one paragraph

Article in The Lancet. Infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Observational
  8. BMJ paediatrics open · 2026
    Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 13 institutions in 10 countries.

Alexander M AikenInfectious Disease Epidemiology Department, London School of Hygiene & Tropical Medicine, London, UK. Electronic address: alexander.aiken@lshtm.ac.uk.
Andrea M RehmanInfectious Disease Epidemiology Department, London School of Hygiene & Tropical Medicine, London, UK.
Marlieke E A de KrakerInfection Control Program and WHO Collaborating Center on Patient Safety and Antimicrobial Resistance, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland.
Lola MadridInfectious Disease Epidemiology Department, London School of Hygiene & Tropical Medicine, London, UK; College of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
Meron KebedeCollege of Health and Medical Sciences, Haramaya University, Harar, Ethiopia.
Appiah-Korang LabiDepartment of Medical Microbiology, University of Ghana Medical School, University of Ghana, Accra, Ghana.
Noah Obeng-NkrumahDepartment of Medical Laboratory Sciences, School of Biomedical and Allied Health Sciences, University of Ghana, Accra, Ghana.
Brian NyamwayaKEMRI Centre for Geographic Medical Research, Kilifi, Kenya.
Eunice KaguciaKEMRI Centre for Geographic Medical Research, Kilifi, Kenya.
Derek CockerDepartment of Medicine, Malawi-Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; David Price Evans Infectious Diseases & Global Health Group, University of Liverpool, Liverpool, UK; Liverpool School of Tropical Medicine, Liverpool, UK.
Kondwani KawazaDepartment of Paediatrics and Child Health, Malawi-Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi.
Rebecca LesterDepartment of Medicine, Malawi-Liverpool Wellcome Programme, Kamuzu University of Health Sciences, Blantyre, Malawi; Liverpool School of Tropical Medicine, Liverpool, UK.
Kenneth C IregbuDepartment of Medical Microbiology, National Hospital Abuja, Abuja, Nigeria.
Nubwa MeduguDepartment of Medical Microbiology, National Hospital Abuja, Abuja, Nigeria; Nile University of Nigeria, Abuja, Nigeria.
Philip I Nwajiobi-PrincewillDepartment of Medical Microbiology, National Hospital Abuja, Abuja, Nigeria.
Angela DramowskiDepartment of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Tolbert SondaKilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Asia HemedKilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
Sombo FwoloshiDepartment of Medicine, University Teaching Hospital, Ministry of Health, Lusaka, Zambia.
David OjokCentre for Infectious Disease Research in Zambia, Lusaka, Zambia.
J Anthony G ScottInfectious Disease Epidemiology Department, London School of Hygiene & Tropical Medicine, London, UK.
Andrew WhitelawDepartment of Medical Microbiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; National Health Laboratory Service, Tygerberg Hospital, Cape Town, South Africa.
MBIRA study collaborators
Kenya Medical Research Institute · KELondon School of Hygiene & Tropical Medicine · GBNational Hospital Abuja · NGKamuzu University of Health SciencesKilimanjaro Christian Medical Centre · TZUniversity of Ghana · GHCentre for Infectious Disease Research in Zambia · ZMHaramaya University · ETLiverpool School of Tropical Medicine · GBStellenbosch University · ZAUniversity of Geneva · CHUniversity Teaching Hospital · ZMWestern Cape Department of Health · ZA

Funding

Wellcome Trust 206545Wellcome Trust 206545/Z/17/Z
6 · The paper itself

Abstract

backgroundBacteria of the order Enterobacterales are common pathogens causing bloodstream infections in sub-Saharan Africa and are frequently resistant to third-generation cephalosporin antibiotics. Although third-generation cephalosporin resistance is believed to lead to adverse outcomes, this relationship is difficult to quantify and has rarely been studied in this region. We aimed to measure the effects associated with resistance to third-generation cephalosporins in hospitalised patients with Enterobacterales bloodstream infection in Africa.

methodsWe conducted a prospective, matched, parallel cohort study at eight hospitals across sub-Saharan Africa. We recruited consecutive patients of all age groups with laboratory-confirmed Enterobacterales bloodstream infection and matched them to at least one patient without bloodstream infection on the basis of age group, hospital ward, and admission date. Date of infection onset (and enrolment) was defined as the day of blood sample collection for culturing. Patients infected with bacteria with a cefotaxime minimum inhibitory concentration of 1 mg/L or lower were included in the third-generation cephalosporin-susceptible (3GC-S) cohort, and the remainder were included in the third-generation cephalosporin-resistant (3GC-R) cohort. The primary outcomes were in-hospital death and death within 30 days of enrolment. We used adjusted multivariable regression models to first compare patients with bloodstream infection against matched patients within the 3GC-S and 3GC-R cohorts, then compared estimates between cohorts.

findingsBetween Nov 1, 2020, and Jan 31, 2022, we recruited 878 patients with Enterobacterales bloodstream infection (221 [25·2%] to the 3GC-S cohort and 657 [74·8%] to the 3GC-R cohort) and 1634 matched patients (420 [25·7%] and 1214 [74·3%], respectively). 502 (57·2%) bloodstream infections occurred in neonates and infants (age 0-364 days). Klebsiella pneumoniae (393 [44·8%] infections) and Escherichia coli (224 [25·5%] infections) were the most common Enterobacterales species identified. The proportion of patients who died in hospital was higher in patients with bloodstream infection than in matched controls in the 3GC-S cohort (62 [28·1%] of 221 vs 22 [5·2%] of 420; cause-specific hazard ratio 6·79 [95% CI 4·06-11·37] from Cox model) and the 3GC-R cohort (244 [37·1%] of 657 vs 115 [9·5%] of 1214; 5·01 [3·96-6·32]). The ratio of these cause-specific hazard ratios showed no significant difference in risk of in-hospital death in the 3GC-R cohort versus the 3GC-S cohort (0·74 [0·42-1·30]). The ratio of relative risk of death within 30 days (0·82 [95% CI 0·53-1·27]) also indicated no difference between the cohorts.

interpretationPatients with bloodstream infections with Enterobacterales bacteria either resistant or susceptible to third-generation cephalosporins had increased mortality compared with uninfected matched patients, with no differential effect related to third-generation cephalosporin-resistance status. However, this finding does not account for time to appropriate antibiotic treatment, which remains clinically important to optimise. Measures to prevent transmission of Enterobacterales could reduce bloodstream infection-associated mortality from both drug-resistant and drug-susceptible bacterial strains in Africa.

fundingBill & Melinda Gates Foundation.

Indexed as

CephalosporinsSepsisAnti-Bacterial AgentsCephalosporin ResistanceCohort StudiesEscherichia coliHospital MortalityHospitalsHumansInfant, NewbornProspective StudiesAnti-Bacterial AgentsCephalosporins

Identifiers

PMID37454672
PMCPMC7617135
OpenAlexW4384156719

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.